The deal size was increased to $130M in common stock from $125M in common stock. Jefferies, JPMorgan and Guggenheim acted as joint book running managers for the offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PROK:
- ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
- ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
- ProKidney announces $125M Class A ordinary shares offering
- ProKidney price target lowered to $6 from $15 at Jefferies
- ProKidney Progresses in Kidney Disease Treatment Trials and Regulation